Interventional radiology

North America Liquid Biopsy Market Report 2020 Featuring Major Players - Exosome Diagnostics, Thermo Fisher Scientific and Bio-Rad Laboratories

Friday, September 18, 2020 - 5:00pm

North America, the liquid biopsy market, is anticipated to reach US$ 3,531.44 Mn in 2027 from US$ 1,651.23 Mn in 2019.

Key Points: 
  • North America, the liquid biopsy market, is anticipated to reach US$ 3,531.44 Mn in 2027 from US$ 1,651.23 Mn in 2019.
  • The liquid biopsy market is growing primarily due to the increasing prevalence of cancer.
  • On the other hand, increasing liquid biopsy due to growing application and advancements is expected to have a positive impact on the growth of the North American liquid biopsy market in the coming years.
  • Exosome Diagnostics Inc., Thermo Fisher Scientific Inc. and Bio-Rad Laboratories Inc. are among the major companies manufacturing liquid biopsy testing products to detect cancer.

DGAP-News: Gradient Denervation Technologies Raises €3.5M in Seed Funding with Sofinnova Partners

Thursday, September 17, 2020 - 7:02am

PARIS, FRANCE / ACCESSWIRE / September 17, 2020 / Gradient Denervation Technologies, a Paris-based medical device company developing a minimally-invasive solution for the treatment of pulmonary hypertension, announced today the close of a 3.5M seed financing from Sofinnova Partners to support the development of its intravascular, catheter-based technology.

Key Points: 
  • PARIS, FRANCE / ACCESSWIRE / September 17, 2020 / Gradient Denervation Technologies, a Paris-based medical device company developing a minimally-invasive solution for the treatment of pulmonary hypertension, announced today the close of a 3.5M seed financing from Sofinnova Partners to support the development of its intravascular, catheter-based technology.
  • Founded in February 2020, Gradient Denervation Technologies ("Gradient") builds on an innovation from two clinicians from Stanford University, Dr. Swami Gnanashanmugam and Dr. Jeffrey Feinstein.
  • Gradient Denervation Technologies develops a device-based minimally invasive solution for the treatment of pulmonary hypertension with technology developed by two clinicians from Stanford University.
  • It is a privately held portfolio company of Sofinnova Partners, financed through the MD Start III Fund and based in Paris, France.

Prytime Medical™ Launches New ER-REBOA™ PLUS Catheter

Thursday, September 17, 2020 - 12:53am

Prytime Medical Devices, Inc. introduced its latest aortic occlusion catheter, the ER-REBOA PLUS this week at the American Association for the Surgery of Trauma (AAST) Annual Meeting.

Key Points: 
  • Prytime Medical Devices, Inc. introduced its latest aortic occlusion catheter, the ER-REBOA PLUS this week at the American Association for the Surgery of Trauma (AAST) Annual Meeting.
  • ER-REBOA PLUS represents the evolution of REBOA based on experience and input from civilian trauma surgeons, said David Spencer, CEO, Prytime.
  • The ER-REBOA PLUS catheter was developed to help doctors preserve their clinical options for optimal care and best outcomes.
  • To learn more about Prytime Medical and the ER-REBOA PLUS Catheter, go to www.prytimemedical.com or call (210) 340-0116.

Shape Memory Medical Announces First Patient Enrollment in AAA-SHAPE Study

Wednesday, September 16, 2020 - 3:00pm

Ted Ruppel, Chief Executive Officer of Shape Memory Medical Inc., said, "We would like to congratulate Dr. Holden, Mr. Hill and the clinical study team at Auckland City Hospital for completing the first procedure in the AAA-SHAPE study.

Key Points: 
  • Ted Ruppel, Chief Executive Officer of Shape Memory Medical Inc., said, "We would like to congratulate Dr. Holden, Mr. Hill and the clinical study team at Auckland City Hospital for completing the first procedure in the AAA-SHAPE study.
  • The IMPEDE-FX Embolization Plug is comprised of Shape Memory Polymer which is a porous, embolic scaffold.
  • We are excited to be part of the AAA-SHAPE study," said Dr. Andrew Holden, principal investigator for the study.
  • Shape Memory Medical Inc., based in Santa Clara, California, is dedicated to developing innovative therapeutic solutions with its proprietary Shape Memory Polymers.

United States Breast Cancer Liquid Biopsy Market Research Report 2020-2025 - Cumulative Impact of COVID-19 - ResearchAndMarkets.com

Wednesday, September 16, 2020 - 8:44am

The "Breast Cancer Liquid Biopsy Market Research Report by Biomarker, by End-User - United States Forecast to 2025 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Breast Cancer Liquid Biopsy Market Research Report by Biomarker, by End-User - United States Forecast to 2025 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.
  • The United States Breast Cancer Liquid Biopsy Market is projected to grow with a significant CAGR in the forecast period.
  • Besides, the qualitative and quantitative parameters provided in the report with detailed analysis highlights the driving and restraining factors of the United States Breast Cancer Liquid Biopsy Market.
  • Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward.

Worldwide Peripheral Vascular Devices Industry to 2025 - Featuring Medtronic, Boston Scientific & Abbott Laboratories Among Others

Tuesday, September 15, 2020 - 3:45pm

9 Endovascular Aneurysm Repair Stent Grafts Market, by Type

Key Points: 

9 Endovascular Aneurysm Repair Stent Grafts Market, by Type
10 Inferior Vena Cava Filters Market, by Type
11 Plaque Modification Devices Market, by Type
12 Hemodynamic Flow Alteration Devices Market, by Type
13 Other Peripheral Vascular Devices Market, by Type

Shockwave Coronary IVL U.S. Pivotal Study Results to be Presented in Late-Breaking Session at TCT Connect

Tuesday, September 15, 2020 - 1:00pm

The webcast event will include remarks from Dr. Dean Kereiakes as well an interactive question and answer session with a panel of experts.

Key Points: 
  • The webcast event will include remarks from Dr. Dean Kereiakes as well an interactive question and answer session with a panel of experts.
  • Shockwave C2 Coronary IVL catheters are commercially available for the treatment of de novo coronary artery disease in Europe and select other geographies; they are limited to investigational use in the United States.
  • DISRUPT CAD III is a prospective, multicenter, single-arm, global IDE study designed to demonstrate the safety and effectiveness of the Shockwave Coronary IVL System with the Shockwave C2 Coronary IVL Catheter in de novo, calcified, stenotic, coronary arteries prior to stenting.
  • The study enrolled 384 patients, exceeding the minimum requirement of 372 patients, per the a priori statistical plan agreed by the FDA.

AIN Is Improving Patient Outcomes Following Surgeries for Brain Aneurysms and Tumors

Tuesday, September 15, 2020 - 12:00pm

The AIN is giving patients more options than ever by providing them access to super-specialized neurosurgeons in the United States.

Key Points: 
  • The AIN is giving patients more options than ever by providing them access to super-specialized neurosurgeons in the United States.
  • Doctors of the AIN have extensive experience and are providing second-opinion consultation services for brain tumors and aneurysms.
  • He added, "Given the complex nature of treating brain tumors and aneurysms, there is a risk of lengthy hospital stays following surgery, risk of having morbidity (having a stroke) following surgery, and the risk of death following surgery.
  • The AIN provides hospitals an opportunity for partnership to improve patient outcomes by decreasing length of stays, morbidity, and mortality.

Global Coronary Stents Market to Surpass US$ 15,109.2 Million by 2027, Says Coherent Market Insights (CMI)

Monday, September 14, 2020 - 3:05pm

According to Coherent Market Insights, the global coronary stents market is estimated to be valued at US$ 8,985.6 million in 2020 and is expected to exhibit a CAGR of 7.7% during the forecast period (2020-2027).

Key Points: 
  • According to Coherent Market Insights, the global coronary stents market is estimated to be valued at US$ 8,985.6 million in 2020 and is expected to exhibit a CAGR of 7.7% during the forecast period (2020-2027).
  • Key Trends and Analysis of the Global Coronary Stents Market:
    Key trends in the market are the increasing incidence of cardiovascular diseases, strategic collaborations and acquisitions among key players, and product launches.
  • Furthermore, key players operating in the global coronary stents market are focusing on launch of novel coronary stents which is expected to drive the market growth during the forecast period.
  • The global coronary stents market is expected to exhibit a CAGR of 7.7% during the forecast period owing to an increasing number of product approvals.

Stratus™ Medical announces two new United States patents issued for the Nimbus® RF Multitined Expandable Electrode used in the treatment of pain

Monday, September 14, 2020 - 1:00pm

SALT LAKE CITY, Sept. 14, 2020 /PRNewswire/ Stratus Medical, a company focused on advancing radiofrequency ablation (RFA) treatment for chronic pain, announced today that the United States Patent and Trademark Office has granted two new patents related to its Nimbus RF Multitined Expandable Electrode.

Key Points: 
  • SALT LAKE CITY, Sept. 14, 2020 /PRNewswire/ Stratus Medical, a company focused on advancing radiofrequency ablation (RFA) treatment for chronic pain, announced today that the United States Patent and Trademark Office has granted two new patents related to its Nimbus RF Multitined Expandable Electrode.
  • 10,716,618, titled System and Methods for Tissue Ablation, issued on July 21, 2020, and U.S. Patent No.
  • About Stratus Medical Stratus Medical is a medical device company focused on reducing pain and suffering and improving the quality of life for chronic pain patients through innovation.
  • Stratus Medical is headquartered in Salt Lake City, Utah where it manufactures the Nimbus RF Multitined Expandable Electrode, which answers the need for an easy-to-use and cost-effective RFA device that provides a large volume lesion to treat pain.